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Cytarabine (cytosine arabinoside, aralC) is a deoxycytidine analogue that is a standard agent for treatment of acute myeloid leukel
mia (AML).1 Cytarabine is intracellularly phosphoryl
lated by deoxycytidine kinase (dCK) to 1lβlDlaral
binofuranoxyl cytosinel5’ltriphosphate (aralCTP).2 
Its cytotoxicity results from a combination of DNA 
polymerase inhibition and incorporation of aralCTP 
into DNA, in competition with deoxycytidine tril
phosphate (dCTP).3,4 This incorporation causes chain 
termination resulting in blockage of DNA synthesis.3 
Cytidine deaminase (CDA) is an enzyme involved in 
the metabolism of cytarabine by converting cytarabine 
into an inactive product (aralU).4 
Nonsynonymous single nucleotide polymorphisms 
(SNPs) of the dCK and CDA genes have been rel
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BACKGROUND: single nucleotide polymorphisms (snps) of deoxycytidine kinase (dcK) and cytidine deami-
nase (cda) are known to alter their enzymatic activities, which affect the metabolism of cytarabine. currently, 
treatment of childhood acute lymphoblastic leukemia (all) includes cytarabine, especially in high-risk patients. 
therefore, we hypothesized that a genetic variation of dCK and CDA genes may influence the risk of cytarabine-
related toxicities and early response to treatment.
PATIENTS AND METHODS: We included children diagnosed with all and lymphoblastic lymphoma (ll) stage 
iii and iV. the patients received a modified st Jude total therapy study XV protocol. cytarabine was used during 
induction remission (low-dose cytarabine) and reinduction ii (high-dose cytarabine) phases. Genotyping of dCK 
-360c>G and -201c>t and CDA 79a>c and 208G>a was performed. minimal residual disease (mrd) at the 
end of the induction phase was measured using flow cytometry. 
RESULTS: ninety-four children with all (n=90) and ll (n=4) were analyzed. the median age at diagnosis was 
5.8 years (range, 0.4-15 years). all four snps showed predominant wild type alleles. there was no CDA-208a 
allele in our population. children with dcK-360G allele were at risk of mucositis after receiving low-dose cyta-
rabine (or=3.7; 95%ci, 1.2--11.3). neither dCK nor CDA polymorphisms affected the mrd status at the end 
of induction phase.
CONCLUSION: the dcK-360G allele was found to increase the risk of mucositis after exposure to low-dose 
cytarabine in childhood all therapy.
ported.5,7 The SNPs at the promoter of dCK gene 
(dCKl360C>G and l201C>T) affect mRNA expresl
sion whose dCKl360G/l201T expresses higher levels 
of dCK mRNA.7 Shi et al demonstrated that AML 
patients with dCKl360CC/l201CC genotype have a 
significant inferior response to therapy as compared 
to the other genotypes.7 The functional variations 
of CDA79A>C and 208G>A have been described 
previously.6,8 The CDA79C and 208A alleles have rel
duced activity compared to wild type alleles in in vitro 
studies.6,8 
Acute lymphoblastic leukemia (ALL) is the most 
common malignancy in childhood. The current treatl
ment of ALL includes cytarabine in several chemotherl
apeutic regimens, especially for highlrisk patients.9l12 
We hypothesized that SNPs of dCK and CDA genes 
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may have an effect on the risk of cytarabinelrelated 
toxicities in children with lymphoid malignancy.
PATIENTS AND METHODS
Children aged less than 15 years old diagnosed with 
ALL and lymphoblastic lymphoma (LL) stage III and 
IV at Ramathibodi Hospital between 2004 and 2008 
were included in this study. The diagnosis of ALL was 
made from an analysis of lymphoblasts from the bone 
marrow. The investigations included morphology, iml
munophenotype, and cytogenetics. LL was diagnosed 
by pathological examination of tumor tissue.
Our institute treated children with ALL and adl
vanced stage LL with a modified St Jude Total Therapy 
Study XV protocol.12 The protocol divided ALL pal
tients into low, standard, and highlrisk groups accordl
ing to age, initial white cell count, cytogenetics, and 
minimal residual disease (MRD) status. The coml
ponents of therapy consisted of induction remission, 
consolidation, intensification (only high risk), reinducl
tion I and II, and maintenance phases. Cytarabine was 
prescribed within remission induction and relinduction 
II phases. Cytarabine 75 mg/m2 (low dose) was given 
subcutaneously on day 23l26 and day 29l32 of the rel
missionlinduction phase for all patients. The patients 
with ALL (standard and high risk) and LL (stage III 
and IV) received cytarabine 2 g/m2 (high dose) inful
sion every 12 hours for 4 doses during the relinduction 
II phase. Common toxicities of cytarabine, including 
anemia, neutropenia, thrombocytopenia, mucositis, dil
arrhea, febrile neutropenia, and delay treatment (more 
than 2 weeks) were recorded and analyzed. The grade 
IIIlIV toxicities were used for statistical analysis of the 
association with dCK and CDA polymorphisms. This 
study protocol was approved by the Ethics Committee 
on Human Experimentation of Faculty of Medicine 
Ramathibodi Hospital, Mahidol University.
Genotyping of dcK and cda polymorphisms 
We collected 3 mL of peripheral blood of patients with 
complete remission for DNA extraction. The DNA 
was extracted by using a standard phenol chloroform 
method. Polymerase chain reaction (PCR) with restricl
tion fragment length polymorphism (RFLP) technique 
was used for detection of dCK l360C>G and l201C>T 
polymorphisms. The reaction mix was composed of 1X 
buffer, 3 mM MgCl2, 0.48 mM dNTPs, 0.2 µM of each 
of the forward and reverse primers, DMSO, 0.06 U/µL 
of Taq and dH2O to the final volume 25 µL. The first 
round PCR reaction was performed using a preldenal
turation step of 5 min at 95°C followed by 20 cycles of 
95°C for 1 min, 61°C for 1 min, and 72ºC for 1 min. 
This was followed by 20 cycles of 95°C for 1 min, 55ºC 
for 1 min, and 72ºC for 1 min and post extension of 
72ºC for 10 min. The primers, restriction enzymes, and 
PCR products are shown in Table 1. 
The CDA 208G>A polymorphism was identified 
by using PCRlRFLP technique. The reaction mix coml
posed of 1X buffer, 3 mM MgCl2, 0.48 mM dNTPs, 
0.2 µM of each of the forward and reverse primers, 0.02 
U/µL of Taq and dH2O to the final volume 25 µL. The 
PCR reaction was performed using a preldenaturation 
step of 95°C for 5 min followed by 35 cycles of 95°C 
for 1 min, 60ºC for 1 min, and 72ºCfor 1 min and final 
extension of 72ºC for 10 min. The primers, restriction 
enzyme, and PCR product are shown in Table 1.
Table 1. Primers, restriction enzymes, and PCR products of dCK and CDA polymorphisms.
Polymorphisms Primers PRC product (base pairs)
Restriction 
enzyme
PRC product 
after digestion 
(base pairs)
dCK -360 C>G
Forward 5’-CTG CAG GTG ACG CCC TCT-3’
469 EhE I
276, 100, 93  (CC)
376, 276, 100, 93  
(CG)
Reverse 5’-GGG TGG CCA TTC CTT AGT CT-3’
376, 93  (GG)
dCK -201 C>T
Forward 5’-CTG CAG GTG ACG CCC TCT-3’
469 BsrB I
469(CC)
469, 259, 210  
(CT)
Reverse 5’-GGG TGG CCA TTC CTT AGT CT-3’
259, 210  (TT)
CDA 208 G>A
Forward 5’-AAC ACA CGC AAC AGG AAG TG-3’
200 Rsr II
114, 86  (GG)
200, 114, 86  (GA)
Reverse  5’-ATT GTT GCA ACC TGG CTT TC-3’ 200  (AA)
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The CDA 79A>C polymorphism was identil
fied by ARMSlPCR technique. Each sample was 
tested in two conditions: (i) the condition for norl
mal homozygous carried out with internal control 
and CDA 79 wild type primers, and (ii) the condil
tion for mutant homozygous carried out with interl
nal control and CDA 79 variant primers. The priml
ers for internal control (βlactin) were forward 5’l
CTAACACTGG CTCGTGTG ACAA Gl3 and 
reverse 5’lGACTC GTCATACTCCTGCTTGCl3’. 
The primers for CDA 79 wild type were forward 5’l
TTGCTC CCAGGAGGCC AAGAl3’ and reverse 
5’lCTTGCCACTGCCTGTGCCTl3’. The varil
ant primers were forward 5’lACCAACATGGCCC 
AGAAGCGl3’ and reverse 5’lGTAGGGGC 
AGTAGGCTGACTGl3’. The reaction mix was coml
posed of 1X buffer, 3 mM MgCl2, 0.48 mM dNTPs, 
0.48 µM of forward and reverse primers of internal conl
trol (βlactin), 0.12 µM (wild type) or 0.2 µM (variant) 
of each of the forward and reverse primer, 0.02 U/µl 
Taq and dH2O to a final volume of 25 µL. The PCR 
reaction was performed at 94°C for 5 min followed by 
35 cycles at 94°C for 30 sec, 68ºC for 30 sec, and 72ºC 
for 1 min and postlextension at 72ºC for 10 min. The 
PCR products were electrophoresed on 2% agarose gel 
and stained with ethidium bromide. 
Minimal residual disease measurement
Flow cytometry analysis was used for detection of 
MRD. Residual leukemic cells were characterized by 
expression of CD19, CD45, CD38/CD34, CD10/
TdT and CD10/CD20 compared to normal B precurl
sors. Briefly, the staining procedure was performed as 
follows: one million leukemic cells were incubated with 
the recommended amount of monoclonal antibodl
iesltolsurface markers in dark surroundings at room 
temperature for 20 minutes. Then red blood cell lysis 
was done by 20lminute incubation with 2 mL FACS 
Lysing Reagents (Beckton Dickinson, San Jose, CA). 
The sample tubes that needed no further intracellular 
staining were washed twice and resuspended in 0.5 mL 
of phosphate buffer saline (PBS) with 0.5% bovine sel
rum albumin and 0.02% NaN3 and 0.5% paraformall
dehyde before being kept in the dark at 4oC while waitl
ing for acquisition. For intracellular staining, after surl
face staining and red blood cell lysis, leukemic cells were 
incubated with 0.5 mL FACS Permeabilizing Reagent 
(Beckton Dickinson, San Jose, CA) for 15 minutes and 
washed. The recommended amount of monoclonal anl
tibody for intracellular markers was added and incul
bated for 10 minutes at room temperature. Cells were 
washed twice and resuspended in PBS (with 0.5% bol
vine serum albumin and 0.02% NaN3) and 0.5% paral
formaldehyde. Afterwards, all samples were analyzed 
by FACScan Flow Cytometer (Beckton Dickinson, San 
Jose, CA). One hundred thousand cells were acquired 
for each tube. List mode data files were analyzed using 
CellQuestPro Program (Beckton Dickinson, San Jose, 
CA). MRD was reported as the percentage of residual 
leukemic cells in all viable nucleated cells. MRD below 
0.01% was reported as negative.
Statistical analysis
The SPSS 16 software package was used for the statisl
tical calculation. Fishers exact and chilsquare tests were 
used for estimation of the association between toxicity 
and genotype or alleles. The odds ratio (OR) with 95% 
confidence interval (CI) was determined.
RESULTS 
Ninetylfour patients (54 males and 40 females) who 
were diagnosed with ALL (n=90) and LL stage III 
(n=4) were included in this study. A median age at diagl
nosis was 5.8 years (range, 0.4l15 years). ALL subtypes 
were precursor B (n=80) and T cell (n=10) lineages.
Distribution of dcK and cda genotypes
The genotype distribution of dCK and CDA polymorl
Table 2. Genotype frequencies of dCK and CDA polymorphisms.
Genotype Cases (%) (n=94)
Controls (%) 
(n=100)
dCK -360 C>G
  CC 68 (72.3) 70 (70)
  CG 25 (26.6) 26 (26)
  GG 1 (1.1) 4 (4)
dCK -201 C>T
  CC 68 (72.3) 70 (70)
  CT 25 (26.6) 26 (26)
  TT 1 (1.1) 4 (4)
CDA 79 A>C
  AA 82 (87.2) 81 (81)
  AC 12 (12.8) 18 (18)
  CC 0 1 (1)
CDA 208 G>A
  GG 94 (100) 100 (100)
  GA 0 0
  AA 0 0
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phisms in cases and controls were as shown in Table 2. 
Wild type was the predominant genotypes of all SNPs. 
The dCK l360 C>G and l201 C>T displayed a linkl
age disequilibrium of each other. The variant allele of 
CDA 208 G>A was not detected in our population. 
The genotype frequencies of these four SNPs were not 
statistically different between cases and controls.
Genetic polymorphisms and cytarabine toxicities
We compared the frequency of common adverse coml
plications occurring after receiving cytarabine (low dose 
and high dose) and genotypes of dCKl360 C>G and 
CDA 79A>C (Table 3 and 4). After exposure to lowl
dose cytarabine, patients with dCKl360 CG or GG genl
otype had a significantly higher risk of mucositis coml
pared to the ones with CC genotype (P=.01) (Table 3). 
The patients with the G allele had an increased risk of 
mucositis with an OR of 3.7 (95%CI, 1.2l11.3). In conl
trast, there was no association between dCKl360 C>G 
Table 3. Association between the genotype of dCK -360 C>G and cytarabine toxicity.
Toxicity
Low dose cytarabine (n=81) High dose cytarabine (n=45)
CC
n=59
n (%)
CG+GG
n=22
n (%)
OR 95% CI
CC
n=29
n (%)
CG=GG
n=16
n (%)
OR 95% CI
Anemia 27 (45.8) 15 (68.2) 2.54 0.90-7.14 10 (34.5) 5 (31.3) 0.86 0.23-3.19
Neutropenia 31 (52.5) 15 (68.2) 1.94 0.69-5.44 13 (44.8) 7 (43.8) 0.96 0.28-3.27
Thrombocytopenia 12 (20.3) 2 (9.1) 0.39 0.08-1.91 20 (69) 10 (62.5) 0.75 0.21-2.70
Mucositis 3 (5.1) 6 (27.3) 7 1.57-31.15 2 (6.9) 1 (6.3) 0.9 0.08-10.77
Diarrhea 5 (8.5) 1 (4.5) 0.51 0.05-4.66 4 (13.8) 2 (12.5) 0.89 0.15-5.51
Febrile neutropenia 14 (23.7) 8 (36.4) 1.84 0.64-5.28 11 (37.9) 5 (31.3) 0.74 0.20-2.72
Delayed treatment 18 (30.5) 6 (27.3) 0.85 0.28-2.54 16 (55.2) 12 (75) 2.44 0.63-9.38
Table 4. Association between the genotype of CDA 79 A>C and cytarabine toxicity.
Toxicity
Low dose cytarabine (n=81) High dose cytarabine (n=45)
AA
n=71
n (%)
AC
n=10
n (%)
OR 95% CI
AA
n=40
n (%)
AC
n=5
n (%)
OR 95% CI
Anemia 37 (52.1) 5 (50) 0.92 0.24-3.45 11 (27.5) 4 (80) 10.55 1.06-105.03
Neutropenia 38 (53.5) 8 (80) 3.47 0.69-17.52 17 (42.5) 3 (60) 2.03 0.31-13.51
Thrombocytopenia 13 (18.3) 1 (10) 0.5 0.06-4.26 26 (65) 4 (80) 2.15 0.22-21.18
Mucositis 9 (12.7) 0 - - 2 (5) 1 (20) 4.75 0.35-64.74
Diarrhea 6 (8.5) 0 - - 6 (15) 0 - -
Febrile neutropenia 20 (28.2) 2 (20) 0.64 0.12-3.27 15 (37.5) 1 (20) 0.42 0.04-4.09
Delayed treatment 22 (31) 2 (20) 0.56 0.11-2.84 24 (60) 4 (80) 2.67 0.27-26.09
genetic variation and the side effects after high dose 
cytarabine. There was no association between CDA 79 
A>C genotype and risk of side effects after either lowl 
or highldose cytarabine administration (Table 4).
Genetic polymorphism and MRD
In the 77 ALL children with available MRD data at the 
end of induction therapy, neither dCK l360 C>G nor 
CDA 79 A>C polymorphism had any significant effect 
on the MRD status (Table 5).
DISCUSSION
In this study, two major enzymes involved in cytarabine 
metabolism were selected and genotyped. We demonl
strated that the frequencies of genetic polymorphisms 
were not similar with previous reports. Our population 
had the dCKl360 G allele frequency of 17%, which was 
similar to Chinese subjects (16%) but higher than in 
whites (2%).5,7 The difference of allele frequencies bel
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Table 5.  Association between genetic polymorphisms and MRD 
at end of induction therapy.
Genotype
MRD status
PPositive 
(n)
Negative 
(n)
dCK -360 C>G
  CC 9 47 0.71
  CG+GG 2 19
CDA 79 A>C
  AA 11 57 0.34
  AC 0 9
tween ethnicities was also seen in CDA 79 A>C polyl
morphism. The Thai population had a CDA 79 C all
lele frequency of 10%, whereas the Japanese and white 
subjects showed allele frequencies of 20% and 33%, rel
spectively.6,13 These data emphasize the importance of 
studying genetic variation individually for each ethnicl
ity. One cannot use others’ data for their research due to 
discordant genetic backgrounds. 
We analyzed the association between the common 
side effects of cytarabine and the genetic polymorl
phisms of its metabolizing enzymes. We showed that 
children with dCKl360 G variant allele had a signifil
cantly greater risk of mucositis than the ones with wild 
type allele after receiving low dose cytarabine. Mucositis 
is one of the common side effects of standardldose cyl
tarabine.4 The dCK l360 G allele was associated with 
higher dCK gene expression; therefore, it may increase 
the active metabolite of cytarabine in both cancer and 
normal cells.7 The effect of the dCK l360 G allele on 
the incidence of mucositis was not found in patients afl
ter high dose cytarabine exposure. The CDA 79 A>C 
polymorphism showed no effect on the side effects of 
cytarabine in our population. In contrast, studies of 
AML patients revealed that CDA polymorphisms were 
associated with the treatmentlrelated complications of 
cytarabine. Bhatla et al reported that AML children 
with CDA 79 CC genotype were at increased risk of 
mucositis after postlinduction chemotherapy.14 Adult 
AML patients with CDA 79 AA genotype had a lower 
incidence of liver toxicity after receiving cytarabinel
based chemotherapy.15 However, both studies did not 
perform genotyping of dCK polymorphism. The effect 
of CDA polymorphism on the side effects of cytarabine 
presents in AML studies may be due to the differences 
in the dosage and other concomitant drugs.  
The MRD status at the end of induction chemol
therapy has proved to be a significant prognostic facl
tor determining the risk of relapse in childhood ALL 
studies.16l18 Therefore, the dCKl360 C>G and CDA79 
A>C alter enzymatic function, and might affect the 
treatment response of cytarabine. However, our data 
did not demonstrate any difference in MRD status 
between patients with wild type and variant. Because 
combination chemotherapy was used in the induction 
phase, the genetic effect of the cytarabine metabolic 
enzymes might be obscured. The treatment of ALL is 
composed of multiple chemotherapeutic agents in each 
phase, which may be a limitation of a study attempting 
to demonstrate the effect of a genetic polymorphism 
affecting metabolism of a single drug on the therapeul
tic outcome. In conclusion, our study has demonstrated 
that the dCKl360 G allele significantly increased the 
risk of mucositis after treatment with cytarabine. This 
finding should encourage clinicians to consider the role 
of genetic variation on the side effects of chemotherapy. 
To minimize the severe toxicities of chemotherapy, furl
ther studies on the polymorphisms of involved metal
bolic enzymes in childhood ALL are warranted.
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